

# Paolo CalabrÃ²

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4798327/publications.pdf>

Version: 2024-02-01

255  
papers

10,656  
citations

43973

48  
h-index

39575

94  
g-index

256  
all docs

256  
docs citations

256  
times ranked

14311  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nuclear factor-kappa B predicts long-term clinical outcome in patients with hypertrophic cardiomyopathy: 10-year follow-up study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e108-e111.	0.8	3
2	Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. <i>Heart Failure Clinics</i> , 2022, 18, 39-49.	1.0	18
3	Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2022, 18, 73-87.	1.0	12
4	Hypertrophic Cardiomyopathy in RASopathies. <i>Heart Failure Clinics</i> , 2022, 18, 19-29.	1.0	33
5	The Risk of Sudden Unexpected Cardiac Death in Children. <i>Heart Failure Clinics</i> , 2022, 18, 115-123.	1.0	16
6	Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry. <i>International Journal of Cardiology</i> , 2022, 349, 31-38.	0.8	4
7	Prognostic implications of ischemia with nonobstructive coronary arteries: Understanding risks for improving treatment. <i>Journal of Internal Medicine</i> , 2022, 291, 112-114.	2.7	0
8	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 278-280.	0.6	1
9	The Biological Role of Vitamins in Athletes' Muscle, Heart and Microbiota. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1249.	1.2	27
10	Natural history of left ventricular hypertrophy in infants of diabetic mothers. <i>International Journal of Cardiology</i> , 2022, 350, 77-82.	0.8	2
11	Anticoagulation After Primary PCI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 264-267.	1.1	2
12	Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference. <i>Neurology International</i> , 2022, 12, 102-108.	0.2	1
13	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	1.6	4
14	A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 1945.	1.0	0
15	A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization. <i>Journal of Clinical Medicine</i> , 2022, 11, 2091.	1.0	0
16	Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study. <i>International Journal of Cardiology</i> , 2022, 354, 22-28.	0.8	12
17	Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA). <i>International Journal of Cardiology</i> , 2022, 354, 7-13.	0.8	14
18	Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 832-841.	0.8	23

#	ARTICLE	IF	CITATIONS
19	Antithrombotic Therapy After TAVI: Evidence, Discordance, and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2022, 20, 318-320.	0.8	0
20	Optimal opportunistic screening of atrial fibrillation using pulse palpation in cardiology outpatient clinics: Who and how. <i>PLoS ONE</i> , 2022, 17, e0266955.	1.1	0
21	Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. <i>Cardiovascular Diabetology</i> , 2022, 21, 77.	2.7	76
22	Thoracic Aortic Dilation: Implications for Physical Activity and Sport Participation. <i>Diagnostics</i> , 2022, 12, 1392.	1.3	5
23	Radial vs Femoral Access in ACS Patients Undergoing Complex PCI Is Associated With Consistent Bleeding Benefit and No Excess of Risks. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1488-1500.	0.8	3
24	Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 3574.	1.0	2
25	Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy. <i>Future Cardiology</i> , 2021, 17, 647-654.	0.5	8
26	Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: The RE-SCORE multicentre prospective registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e36-e38.	0.8	7
27	Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.	1.0	21
28	Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial) Tj ETQq0 0 0 rgBT, /Overlock 10 Tf 50 1143-1150.	0.7	1
29	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry. <i>International Journal of Cardiology</i> , 2021, 325, 109-114.	0.8	19
30	Rheumatic mitral stenosis in a 28-week pregnant woman treated by mitral valvuoplasty guided by low dose of radiation: a case report and brief overview. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 364-366.	0.4	0
31	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 904.	1.2	32
32	Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1583-1591.	1.0	9
33	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 375-388.	1.2	70
34	Rare case of Kawasaki disease with cardiac tamponade and giant coronary artery aneurysms. <i>Cardiology in the Young</i> , 2021, 31, 865-866.	0.4	3
35	Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes. <i>Frontiers in Pediatrics</i> , 2021, 9, 632293.	0.9	43
36	Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 361-373.	1.1	25

#	ARTICLE	IF	CITATIONS
37	Genetic Susceptibility to SARS-CoV-2: From the Neandertal Age to 2020. <i>Neurology International</i> , 2021, 11, 28-30.	0.2	0
38	Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy. <i>Pharmaceuticals</i> , 2021, 14, 290.	1.7	1
39	Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events. <i>Journal of Clinical Medicine</i> , 2021, 10, 1721.	1.0	2
40	Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve. <i>Pediatric Cardiology</i> , 2021, 42, 1133-1140.	0.6	9
41	Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 424-426.	0.8	1
42	Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, .	0.3	0
43	Troponin T Mutation as a Cause of Left Ventricular Systolic Dysfunction in a Young Patient with Previous Surgical Correction of Aortic Coarctation. <i>Biomolecules</i> , 2021, 11, 696.	1.8	4
44	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5863.	1.8	48
45	Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108959.	1.1	42
46	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1170-1179.	0.4	4
47	Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter. <i>International Journal of Cardiology</i> , 2021, 339, 243-245.	0.8	2
48	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 381.	1.2	12
49	Advanced Heart Failure in Special Population – Pediatric Age. <i>Heart Failure Clinics</i> , 2021, 17, 673-683.	1.0	6
50	Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 755.	0.5	45
51	Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 151-161.	0.6	53
52	Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13.	0.8	35
53	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
54	New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. <i>Heart Failure Clinics</i> , 2021, 18, 177-188.	1.0	14

#	ARTICLE	IF	CITATIONS
55	Long-Term Variation in Kidney Function and Its Impact After Acute Myocardial Infarction. American Journal of Cardiology, 2021, , .	0.7	0
56	Coronary stent thickness: thinner is (always) better for all lesions?. Journal of Cardiovascular Medicine, 2021, 22, 26-28.	0.6	1
57	Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. Diagnostics, 2021, 11, 2144.	1.3	11
58	CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	0
59	MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. Neurology International, 2021, 11, 230-254.	0.2	1
60	585â€fNatural history of left ventricular hypertrophy in infants of diabetic mothers. European Heart Journal Supplements, 2021, 23, .	0.0	0
61	Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis.. Journal of Cardiovascular Echography, 2021, 31, 157-164.	0.1	2
62	589â€fExternal validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis. European Heart Journal Supplements, 2021, 23, .	0.0	0
63	Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. European Journal of Preventive Cardiology, 2020, 27, 556-558.	0.8	39
64	Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 299, 186-191.	0.8	58
65	Assessment of residual thrombus burden in patients with STâ€segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Tj ETQq1 1 0.784314 rgBT /Qverlock Cardiovascular Interventions. 2020, 96, 1156-1171.	0.7	2
66	Childhood obesity: an overview of laboratory medicine, exercise and microbiome. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1385-1406.	1.4	11
67	Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry. Angiology, 2020, 71, 235-241.	0.8	3
68	Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease. Cardiology Clinics, 2020, 38, 575-588.	0.9	5
69	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. Atherosclerosis, 2020, 312, 72-78.	0.4	25
70	Lugar de acceso y tipo de anticoagulante en pacientes con sÃndrome coronario agudo en clase Killip avanzada o con parada cardiaca extrahospitalaria. Revista Espanola De Cardiologia, 2020, 73, 893-901.	0.6	5
71	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. Archives of Cardiovascular Diseases, 2020, 113, 642-651.	0.7	9
72	Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies. International Journal of Molecular Sciences, 2020, 21, 6462.	1.8	38

#	ARTICLE	IF	CITATIONS
73	Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 173-180.	0.8	31
74	Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9424.	1.2	23
75	Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 559-570.	1.0	7
76	Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases. <i>PLoS ONE</i> , 2020, 15, e0233050.	1.1	13
77	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 893-901.	0.4	7
78	Methicillin-Resistant <i>Staphylococcus aureus</i> : Risk for General Infection and Endocarditis Among Athletes. <i>Antibiotics</i> , 2020, 9, 332.	1.5	8
79	Do we need a redefinition of the cardiovascular risk categories used in the 2019 ESC/EAS guidelines on dyslipidaemias?. <i>European Heart Journal</i> , 2020, 41, 2332-2332.	1.0	2
80	Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. <i>BioFactors</i> , 2020, 46, 367-380.	2.6	46
81	Population Trends in Rates of Percutaneous Coronary Revascularization for Acute Coronary Syndromes Associated With the COVID-19 Outbreak. <i>Circulation</i> , 2020, 141, 2035-2037.	1.6	107
82	Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome. <i>Cardiology in the Young</i> , 2020, 30, 663-667.	0.4	5
83	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. <i>European Heart Journal</i> , 2020, 41, 2083-2088.	1.0	716
84	Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. <i>Current Vascular Pharmacology</i> , 2020, 18, 294-301.	0.8	8
85	Therapeutic Considerations with Revascularization in Chronic Kidney Disease: Radial Versus Femoral Arterial Access. , 2020, , 85-101.		0
86	Title is missing!. , 2020, 15, e0233050.		0
87	Title is missing!. , 2020, 15, e0233050.		0
88	Title is missing!. , 2020, 15, e0233050.		0
89	Title is missing!. , 2020, 15, e0233050.		0
90	Title is missing!. , 2020, 15, e0233050.		0

#	ARTICLE	IF	CITATIONS
91	Title is missing!. , 2020, 15, e0233050.		0
92	Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry. <i>Angiology</i> , 2019, 70, 257-263.	0.8	21
93	Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry. <i>PLoS ONE</i> , 2019, 14, e0219676.	1.1	16
94	Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2116-2118.	1.1	6
95	Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.	0.7	20
96	Event recurrence after myocardial infarction: Prediction is very difficult, especially about the future. <i>International Journal of Cardiology</i> , 2019, 296, 30-31.	0.8	6
97	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. <i>Journal of Electrocardiology</i> , 2019, 57, 44-54.	0.4	7
98	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 934-936.	2.3	3
99	Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 435-447.	0.6	24
100	Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study. <i>BioMed Research International</i> , 2019, 2019, 1-6.	0.9	6
101	Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. <i>Cardiovascular Diabetology</i> , 2019, 18, 24.	2.7	78
102	Laboratory medicine: health evaluation in elite athletes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1450-1473.	1.4	25
103	Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. <i>Internal and Emergency Medicine</i> , 2019, 14, 621-625.	1.0	37
104	Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 758-774.	1.2	22
105	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019, 286, 226-233.	0.8	28
106	Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?. <i>European Heart Journal</i> , 2019, 40, 216-217.	1.0	32
107	A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 417-434.	1.1	81
108	Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry). <i>International Journal of Cardiology</i> , 2018, 258, 50-54.	0.8	6



#	ARTICLE	IF	CITATIONS
109	Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. <i>Atherosclerosis</i> , 2018, 269, 219-228.	0.4	67
110	Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 83-90.	0.6	13
111	Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-year follow-up of a propensity score matching comparison (the BIOROLVE-ISR Study). <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 668-677.	0.7	6
112	Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 75-77.	0.6	34
113	Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. <i>American Heart Journal</i> , 2018, 196, 113-118.	1.2	7
114	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 36-50.	1.1	47
115	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	1.0	22
116	Simulation Models of Therapy Intensification in Lipid-Lowering Medicine. <i>JAMA Cardiology</i> , 2018, 3, 88.	3.0	1
117	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. <i>International Journal of Cardiology</i> , 2018, 259, 20-25.	0.8	18
118	Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry. <i>Angiology</i> , 2018, 69, 795-802.	0.8	35
119	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1231-1242.	1.2	32
120	Clinical outcomes of overlapping versus non-overlapping everolimus-eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov) <a href="https://doi.org/10.1093/eurheartj/ehy010">https://doi.org/10.1093/eurheartj/ehy010</a>	0.7	16
121	Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. <i>Angiology</i> , 2018, 69, 103-112.	0.8	8
122	Radial Versus Femoral Access for Coronary Angiography. <i>Angiology</i> , 2018, 69, 286-287.	0.8	3
123	von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 249-260.	1.5	35
124	Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy. <i>Journal of Cellular Biochemistry</i> , 2018, 181, 156-168.		102
125	Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up. <i>Cardiovascular Diabetology</i> , 2018, 17, 152.	2.7	48
126	Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E518-E526.	0.7	43



#	ARTICLE	IF	CITATIONS
127	Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?. Expert Review of Cardiovascular Therapy, 2018, 16, 951-962.	0.6	24
128	“Full-plastic jacket” with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413). International Journal of Cardiology, 2018, 266, 67-74.	0.8	4
129	Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). American Journal of Cardiology, 2018, 122, 936-943.	0.7	12
130	Letter by Calabrà et al Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)” Circulation, 2018, 138, 218-219.	1.6	0
131	Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. Diabetology and Metabolic Syndrome, 2018, 10, 1.	1.2	102
132	Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines. Internal and Emergency Medicine, 2018, 13, 1185-1190.	1.0	6
133	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	6.3	215
134	Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. International Journal of Cardiology, 2018, 273, 8-14.	0.8	18
135	Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience. Current Vascular Pharmacology, 2018, 17, 92-98.	0.8	2
136	The left atrial appendage: from embryology to prevention of thromboembolism. European Heart Journal, 2017, 38, ehw159.	1.0	53
137	Cardiovascular calcification and subcortical bone demineralization in hypertension. Hypertension Research, 2017, 40, 825-830.	1.5	5
138	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Advances in Therapy, 2017, 34, 1200-1210.	1.3	56
139	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	1.2	132
140	Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding. Cardiovascular Revascularization Medicine, 2017, 18, 425-430.	0.3	11
141	Radiation Exposure and Vascular Access in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2017, 69, 2530-2537.	1.2	61
142	Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.7	10
143	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2017, 44, 355-361.	1.0	9
144	Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions. Journal of Cardiovascular Medicine, 2017, 18, 580-589.	0.6	8

#	ARTICLE	IF	CITATIONS
145	Letter by Calabrà <sup>2</sup> and Gagnano Regarding Article, "Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials" Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	2
146	Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News?. American Journal of Medicine, 2017, 130, e515.	0.6	1
147	Letter by Natale et al Regarding Article, "Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort) Tj ETQq1 1 0.784314 rgBT /@overlock 10	1.4	173
148	Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Therapeutic Advances in Drug Safety, 2017, 8, 67-75.	1.0	40
149	From Femoral to Radial Approach in Coronary Intervention. Angiology, 2017, 68, 281-287.	0.8	21
150	Upregulation of TH/IL-17 Pathway-Related Genes in Human Coronary Endothelial Cells Stimulated with Serum of Patients with Acute Coronary Syndromes. Frontiers in Cardiovascular Medicine, 2017, 4, 1.	1.1	28
151	The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators of Inflammation, 2017, 2017, 1-13.	1.4	173
152	Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS ONE, 2017, 12, e0186961.	1.1	21
153	Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target. Current Vascular Pharmacology, 2017, 15, 404-415.	0.8	28
154	Pathogenesis of Takotsubo Syndrome. Neurology International, 2016, 6, 5973.	0.2	0
155	Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. Cardiovascular Drugs and Therapy, 2016, 30, 465-472.	1.3	5
156	Editor's Choice-Biomarkers of acute cardiovascular and pulmonary diseases. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 416-433.	0.4	39
157	Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. Journal of Cardiovascular Translational Research, 2016, 9, 40-48.	1.1	9
158	Genetics of Takotsubo Syndrome. Heart Failure Clinics, 2016, 12, 499-506.	1.0	19
159	A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience. International Journal of Cardiology, 2016, 224, 454-455.	0.8	21
160	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ, The, 2016, 354, i4935.	3.0	43
161	The Role of the Atrial Electromechanical Delay in Predicting Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients. Journal of Cardiovascular Electrophysiology, 2016, 27, 65-72.	0.8	32
162	Effects of Transcatheter Aortic Valve Implantation on Left Ventricular and Left Atrial Morphology and Function. Echocardiography, 2015, 32, 928-936.	0.3	33

#	ARTICLE	IF	CITATIONS
163	Acute kidney injury after percutaneous coronary intervention: Rationale of the <sc>AKI-MATRIX</sc> (acute kidney injuryâ€minimizing adverse hemorrhagic events by TRansradial access site and systemic) Tj ETQq1 1 0.78431439 BT /Over 2015, 86, 950-957.	0.7	39
164	Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry. Journal of Cardiovascular Medicine, 2015, 16, 520-521.	0.6	1
165	Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. International Journal of Cardiology, 2015, 199, 366-372.	0.8	34
166	Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. European Heart Journal, 2015, 36, 1242-1251.	1.0	76
167	ST2 marker might help to stratify in-hospital high risk patients with Tako-tsubo cardiomyopathy. European Journal of Internal Medicine, 2015, 26, 144-145.	1.0	5
168	Activating stimuli induce platelet microRNA modulation and proteome reorganisation. Thrombosis and Haemostasis, 2015, 114, 96-108.	1.8	40
169	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet, The, 2015, 385, 2465-2476.	6.3	1,043
170	Which Hemodynamic Parameter Predicts Nitroglycerinâ€Potentiated Headâ€Up Tilt Test Response?. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 507-513.	0.5	7
171	Venous thromboembolism and lung cancer: a review. Multidisciplinary Respiratory Medicine, 2015, 10, 28.	0.6	56
172	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 997-1009.	13.9	334
173	Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on Î²1 and Î²2-adrenergic receptors polymorphisms?. International Journal of Cardiology, 2015, 199, 189-192.	0.8	10
174	Atypical â€vacuumâ€inside of neoatherosclerosis long term after DES implantation: Insights from optical coherence tomography. International Journal of Cardiology, 2015, 199, 221-222.	0.8	0
175	Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Nonâ€ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 1117-1127.	1.1	38
176	Preoperative evaluation before MitraClip <sup>®</sup> : present and future perspective. Future Cardiology, 2014, 10, 725-744.	0.5	1
177	Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX â€ RADIation Dose study (RAD-MATRIX). Cardiovascular Revascularization Medicine, 2014, 15, 209-213.	0.3	17
178	Effect of cardiac resynchronization therapy on cardiotrophin-1 circulating levels in patients with heart failure. Internal and Emergency Medicine, 2014, 9, 43-50.	1.0	9
179	Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial. Journal of Cardiovascular Translational Research, 2014, 7, 101-111.	1.1	42
180	Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. Current Atherosclerosis Reports, 2014, 16, 435.	2.0	413

#	ARTICLE	IF	CITATIONS
181	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	1.0	78
182	Adipose tissue and vascular inflammation in coronary artery disease. <i>World Journal of Cardiology</i> , 2014, 6, 539.	0.5	42
183	Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. <i>Journal of Invasive Cardiology</i> , 2014, 26, 563-9.	0.4	24
184	Takotsubo Cardiomyopathy. <i>Heart Failure Clinics</i> , 2013, 9, 207-216.	1.0	25
185	Rapid ultrasound score as an indicator of atherosclerosis clinical manifestations in a population of hypertensives. <i>Anatolian Journal of Cardiology</i> , 2013, 14, 9-15.	0.4	1
186	Routine evaluation of abdominal aorta diameter at the end of transthoracic echocardiography in hypertensive patients. Why not?. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 748-749.	0.6	0
187	Peri-Procedural Tight Glycemic Control during Early Percutaneous Coronary Intervention Is Associated with a Lower Rate of In-Stent Restenosis in Patients with Acute ST-Elevation Myocardial Infarction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2862-2871.	1.8	73
188	Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 4-16.	0.9	55
189	Diagnosis and Management of Atrial Fibrillation by Primary Care Physicians in Italy. <i>Clinical Drug Investigation</i> , 2012, 32, 771-777.	1.1	8
190	Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. <i>Internal and Emergency Medicine</i> , 2012, 7, 425-430.	1.0	27
191	Global longitudinal speckle-tracking strain is predictive of left ventricular remodeling after coronary angioplasty in patients with recent non-st elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2011, 153, 185-191.	0.8	55
192	C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2011, 152, 7-12.	0.8	39
193	Which is the correct management of patients with asymptomatic severe calcific aortic stenosis after symptomatic spontaneous calcium cerebral embolism?. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 428-429.	0.6	1
194	Contemporary evidence of coronary atherosclerotic disease and myocardial bridge on left anterior descending artery in a patient with a nonobstructive hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 510-512.	0.6	1
195	Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography. <i>Internal and Emergency Medicine</i> , 2011, 6, 503-507.	1.0	12
196	Tissue Factor Is Induced by Resistin in Human Coronary Artery Endothelial Cells by the NF- $\kappa$ B-Dependent Pathway. <i>Journal of Vascular Research</i> , 2011, 48, 59-66.	0.6	58
197	A new character on the scene of cardiorenal syndrome. <i>Hypertension Research</i> , 2011, 34, 996-996.	1.5	0
198	Worsening of rosacea in patients treated with dihydropyridine calcium channel blockers: a clinical observation. <i>Hypertension Research</i> , 2011, 34, 790-791.	1.5	9

#	ARTICLE	IF	CITATIONS
199	Inflammation: The Link Between Obesity and Cardiovascular Risk. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 101-111.	0.8	1
200	Management of Patients With Asymptomatic Severe Aortic Stenosis and Severe Anemia. <i>American Journal of Cardiology</i> , 2010, 105, 423.	0.7	2
201	Clinical Course and Risk Profile in Adolescents With Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 2010, 105, 716-720.	0.7	5
202	Left Ventricular Non Compaction in Children. <i>Congenital Heart Disease</i> , 2010, 5, 384-397.	0.0	21
203	Hypertrophic cardiomyopathy in a girl with Cornelia de Lange syndrome due to mutation in <i>SMC1A</i> . <i>American Journal of Medical Genetics, Part A</i> , 2010, 152A, 2127-2129.	0.7	23
204	Thyroid function derangement and childhood obesity: an Italian experience. <i>BMC Endocrine Disorders</i> , 2010, 10, 8.	0.9	61
205	Effect of body mass index reduction on serum hepcidin levels and iron status in obese children. <i>International Journal of Obesity</i> , 2010, 34, 1772-1774.	1.6	94
206	Cardiotrophin-1 and TNF- $\alpha$ circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. <i>Cytokine</i> , 2010, 50, 245-247.	1.4	13
207	Left atrial volume index in highly trained athletes. <i>American Heart Journal</i> , 2010, 159, 1155-1161.	1.2	153
208	Evidence of right coronary from mid-left anterior descending coronary: a rare case of coronary anomalous origin. <i>European Heart Journal</i> , 2009, 30, 565-565.	1.0	11
209	Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives. <i>European Journal of Echocardiography</i> , 2009, 10, 549-555.	2.3	166
210	Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?. <i>Internal and Emergency Medicine</i> , 2009, 4, 25-34.	1.0	75
211	CRP and the risk of atherosclerotic events. <i>Seminars in Immunopathology</i> , 2009, 31, 79-94.	2.8	103
212	Right Ventricular Myocardial Function in Patients with Either Idiopathic or Ischemic Dilated Cardiomyopathy Without Clinical Sign of Right Heart Failure: Effects of Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 1017-1029.	0.5	39
213	Clinical Outcome in Patients with Intermediate Stenosis of Left Anterior Descending Coronary Artery after Deferral of Revascularization on the Basis of Noninvasive Coronary Flow Reserve Measurement. <i>Echocardiography</i> , 2009, 26, 431-440.	0.3	9
214	A child cohort study from southern Italy enlarges the genetic spectrum of hypertrophic cardiomyopathy. <i>Clinical Genetics</i> , 2009, 76, 91-101.	1.0	39
215	Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 46, 142-148.	0.9	50
216	Association between left atrial myocardial function and exercise capacity in patients with either idiopathic or ischemic dilated cardiomyopathy: A two-dimensional speckle strain study. <i>International Journal of Cardiology</i> , 2009, 132, 354-363.	0.8	81

#	ARTICLE	IF	CITATIONS
217	Hepcidin in Obese Children as a Potential Mediator of the Association between Obesity and Iron Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 5102-5107.	1.8	164
218	Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight into global cardiometabolic risk. <i>Current Hypertension Reports</i> , 2008, 10, 32-38.	1.5	72
219	Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2008, 146A, 620-628.	0.7	47
220	The role of adiposity as a determinant of an inflammatory milieu. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 450-460.	0.6	33
221	Severe, early onset hypertrophic cardiomyopathy in a family with LEOPARD syndrome. <i>Journal of Prenatal Medicine</i> , 2008, 2, 24-6.	0.2	5
222	Inflammation may modulate IL-6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E1030-E1035.	1.8	42
223	Effect of dynamic myocardial dyssynchrony on mitral regurgitation during supine bicycle exercise stress echocardiography in patients with idiopathic dilated cardiomyopathy and 'narrow' QRS. <i>European Heart Journal</i> , 2007, 28, 1004-1011.	1.0	60
224	HMG-CoA Reductase Inhibitors Reduce Nicotine-Induced Expression of Cellular Adhesion Molecules in Cultured Human Coronary Endothelial Cells. <i>Journal of Vascular Research</i> , 2007, 44, 460-470.	0.6	25
225	Different effects of cardiac resynchronization therapy on left atrial function in patients with either idiopathic or ischaemic dilated cardiomyopathy: a two-dimensional speckle strain study. <i>European Heart Journal</i> , 2007, 28, 2738-2748.	1.0	103
226	Obesity, Inflammation, and Vascular Disease. <i>Sub-Cellular Biochemistry</i> , 2007, , 63-91.	1.0	82
227	Prevalence and Clinical Significance of Cardiovascular Abnormalities in Patients With the LEOPARD Syndrome. <i>American Journal of Cardiology</i> , 2007, 100, 736-741.	0.7	150
228	Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight in the global cardiometabolic risk. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 32-38.	0.8	4
229	Inflammation, C-Reactive Protein, and Vulnerable Plaques. , 2007, , 611-620.		2
230	Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. <i>Sub-Cellular Biochemistry</i> , 2007, 42, 63-91.	1.0	31
231	Diffuse coronary dilation in a young patient with LEOPARD syndrome. <i>International Journal of Cardiology</i> , 2006, 112, E35-E37.	0.8	11
232	The athlete's heart and hypertrophic cardiomyopathy: two conditions which may be misdiagnosed and coexistent. Which parameters should be analysed to distinguish one disease from the other?. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 257-266.	0.6	12
233	Potential clinical perspectives of Doppler myocardial imaging and strain rate imaging during stress echocardiography. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 480-490.	0.6	0
234	Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 711-713.	0.6	8



#	ARTICLE	IF	CITATIONS
235	Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2248-2255.	1.9	39
236	Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2006, 27, 1311-1318.	1.0	59
237	Abnormal myocardial deformation properties in obese, non-hypertensive children: an ambulatory blood pressure monitoring, standard echocardiographic, and strain rate imaging study. <i>European Heart Journal</i> , 2006, 27, 2689-2695.	1.0	144
238	The pleiotropic effects of statins. <i>Current Opinion in Cardiology</i> , 2005, 20, 541-546.	0.8	138
239	C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. <i>Cardiovascular Research</i> , 2005, 68, 47-55.	1.8	126
240	Atrial Myocardial Deformation Properties Predict Maintenance of Sinus Rhythm After External Cardioversion of Recent-Onset Lone Atrial Fibrillation. <i>Circulation</i> , 2005, 112, 387-395.	1.6	243
241	Inhibition of Tumor-Necrosis-Factor- $\alpha$ -Induced Endothelial Cell Activation by a New Class of PPAR- $\gamma$ Agonists. <i>Journal of Vascular Research</i> , 2005, 42, 509-516.	0.6	20
242	Release of C-Reactive Protein in Response to Inflammatory Cytokines by Human Adipocytes: Linking Obesity to Vascular Inflammation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1112-1113.	1.2	247
243	Resistin Promotes Smooth Muscle Cell Proliferation Through Activation of Extracellular Signal-Regulated Kinase 1/2 and Phosphatidylinositol 3-Kinase Pathways. <i>Circulation</i> , 2004, 110, 3335-3340.	1.6	291
244	Tissue Factor Binding of Activated Factor VII Triggers Smooth Muscle Cell Proliferation via Extracellular Signal-Regulated Kinase Activation. <i>Circulation</i> , 2004, 109, 2911-2916.	1.6	63
245	Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: Beyond cardiovascular diseases. <i>Current Atherosclerosis Reports</i> , 2004, 6, 36-41.	2.0	10
246	Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 992-998.	1.9	11
247	Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells. <i>Circulation</i> , 2003, 108, 1930-1932.	1.6	477
248	Activated platelets stimulate tissue factor expression in smooth muscle cells. <i>Thrombosis Research</i> , 2003, 112, 51-57.	0.8	23
249	Left ventricular remodeling, mechanics, and tissue characterization in congenital aortic stenosis. <i>Journal of the American Society of Echocardiography</i> , 2003, 16, 214-220.	1.2	30
250	Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1684-1689.	1.1	8
251	Feasibility and usefulness of right ventricular ultrasonic tissue characterization with integrated backscatter in patients with unsuccessfully operatively repaired tetralogy of Fallot. <i>American Journal of Cardiology</i> , 2002, 90, 669-671.	0.7	9
252	Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. <i>Journal of the American College of Cardiology</i> , 2001, 38, 569-576.	1.2	37



#	ARTICLE	IF	CITATIONS
253	A Simple Method for the Isolation, Cultivation, and Characterization of Endothelial Cells from Rabbit Coronary Circulation. <i>Thrombosis Research</i> , 1999, 96, 329-333.	0.8	11
254	Echocardiographic Evaluation of Left Ventricular Systolic Function in the Down Syndrome 22Dr. Bruno Marino is supported by Telethon-Italy n. E.C. 496.. <i>American Journal of Cardiology</i> , 1998, 81, 1215-1217.	0.7	17
255	Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. <i>Clinical Cardiology</i> , 0, , .	0.7	5